No 03 2015

The US Food and Drug Administration (FDA) has accepted and granted Priority Review to Alexion, AstraZeneca's Rare Disease unit, for efzimfotase alfa as a treatment for patients with hypophosphatasia (HPP) aged 2 years and older.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Pepaxti (melflufen) be extended to earlier lines of multiple myeloma treatment, a move that would significantly widen the drug's eligible patient population.

Teitur Trophics' co-founder and CEO Simon Mølgaard was named Rising Star in Danish Biotech at the DANISH BIO – Dansk Biotek Spring Gala in April 2026. Nordic Life Science asked him about the transition from science to business, building a company from Aarhus, and the opportunities ahead in treating neurodegenerative disease.

Orbis Medicines has entered a strategic collaboration and license agreement with Novo Nordisk to discover and develop next-generation oral macrocycle therapeutics for cardiometabolic diseases, in a deal worth up to USD 1.4 billion.

Over the course of her career, Anna Sundin has worked on numerous transactions spanning capital raises, IPOs, M&A, and debt financing, as well as providing strategic advice to companies in a growth phase.

A newly published, peer-reviewed study has used Lumito's SCIZYS tissue-imaging platform to analyse biomarker expression in single immune cells, extending its validated use beyond tissue samples into cell-based research for the first time.

The company is to separate its Operating Room Solutions (ORS) and Gloves businesses into a new standalone company, provisionally named 'Mölnlycke Surgical', while Wound Care and Antiseptics continue as Mölnlycke.